PCSK9 inhibitors reduce cardiovascular events, preliminary data showBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1508 (Published 17 March 2015) Cite this as: BMJ 2015;350:h1508
- Susan Mayor
Two investigational drugs from a new class of lipid lowering agents—the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors—significantly reduce cardiovascular events, new exploratory analyses have shown.
PCSK9 promotes the degradation of low density lipoprotein (LDL) receptors, so blocking its action increases the levels of receptor, which facilitates the clearance of LDL cholesterol.
The studies, reported in the New England Journal of Medicine, investigated the efficacy and safety of two monoclonal antibodies that inhibit PCSK9 and showed that they …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial